RoundTable Healthcare Partners overview
Stories about RoundTable Healthcare Partners
RoundTable to sell generic drug co for $565m
Swiss drug giant Novartis has agreed to buy Sabex from RoundTable Healthcare Partners, scoring a 150 percent gross return on its overall investment.
RoundTable Healthcare Partners contact information
Offices
272 East Deerpath Road, Suite 350, Lake Forest, 60045, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Ms. Bernadette Legarreta | Job titleOperating Partner, Chief Financial Officer and Chief Compliance Officer | LocationLake Forest, United States | Email  ------ |
| Key ContactMr. Thomas P. Kapfer | Job titleManaging Partner | LocationLake Forest, United States | Email ------- |
| Mr. R. Craig Collister | Job titleManaging Partner | LocationLake Forest, United States | Email -------- |
| Mr. Pierre Fréchette | Job titleManaging Partner and Senior Advisor | LocationLake Forest, United States | Email ------ |
RoundTable Healthcare Partners funds managed
Closed funds: 6
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ----------- | Close dateMay 2022 | Strategy ------ | |
Fund size ----- | Close dateJul 2019 | Strategy ----------- | |
Fund size ------- | Close dateSep 2015 | Strategy -------- | |
Stories that mention RoundTable Healthcare Partners
RoundTable seals $403m pharmaceutical exit
The firm’s sale of Aqua Pharmaceuticals marks RoundTable’s third exit from its $500m Fund II.
GPs react to Supreme Court healthcare ruling
The US Supreme Court's decision to uphold President Barack Obama's healthcare reform law should lead to a better environment for investing in healthcare businesses.
RoundTable raises $800m for healthcare
Healthcare reform in the US will create opportunities over the next five years, according to RoundTable co-chair Lester Knight.
RoundTable closes second fund on $500m
Three years after finding $400m for its first fund, the healthcare specialist has raised a fresh pool of capital.
RoundTable acquires syringe maker
The Chicago firm's purchase of Excelsior Medical follows its successful exit of injectable generic drug maker Sabex to Novartis for $565m.